Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03777033
Other study ID # Ca/vitD in thyroidectomy
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2015
Est. completion date August 4, 2020

Study information

Verified date September 2019
Source Hellenic Red Cross Hospital
Contact SOPHOCLES LANITIS, M.D, PhD
Phone 00306974445355
Email drlanitis@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Transient hypocalcaemia consist the most common postoperative complication after thyroidectomy (10-45%). It may be mild and subclinical or cause mild or severe symptoms and may lead to longer hospital stay as well as in discomfort of the patients. For the management oral or intravenous calcium with or without vitamin D administration can be used based on the blood calcium levels and on the symptomatology. The investigators intent to study a new protocol with oral calcium and vitamin D given systematically from the day of operation to assess if this practice can minimize the rate of transient hypocalcaemia and as a consequence minimize the length of stay in the hospital.


Description:

Transient hypocalcaemia consist the most common postoperative complication after thyroidectomy (10-45%). It may be mild and subclinical or cause mild or severe symptoms and may lead to longer hospital stay as well as in discomfort of the patients. For the management oral or intravenous calcium with or without vitamin D administration can be used based on the blood calcium levels and on the symptomatology.

Group A = control group will be managed as usual. Oral or IV supplements of Calcium will be giver on demand and recorded according to the clinical picture or the biochemical hypocalcaemia.

Group B= study group will be given systematically from the day of operation a scheme with oral calcium in the form of 1000ca++mg/tab and oral alfacalcidol in the form of 0.5 micrograms/tb The patients will receive one tablet three times a day oral calcium (3g/d) and 2 tablets , two times a day alfacalcidiol (2 micrograms/d) for the first 5 days. Afterwards they will be taking 2 tablets a day of oral calcium ( 2g) and 2 tablets a day alfacalcidiol (1micrograms/d) for another 10 days ( total 15 days) The investigators intent to minimize the immediate transient hypocalcaemia rate and give time to the parathyroids which may have been bruised or have compromised function initially to recover by day 15.

The 1st and 2nd postoperative day the invastigators are going to take blood samples and assess the 25 hydroxy vit D, the parathyroid hormone (PTH) and the Ca++. The investigators will also assess the calcium levels after the first week and if necessary ( in cases with longstanding hypocalcaemia ) in later day.

The patients will be discharged from the hospital the day after the operation provided the calcium levels are within normal range and they are completely asymptomatic.

In case of symptoms after the discharge the patients will be managed accordingly and this will be recorded in the records of each patient


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date August 4, 2020
Est. primary completion date April 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 90 Years
Eligibility Inclusion Criteria:

- Thyroid pathology only

- No calcium metabolism problems

- Total / near total thyroidectomy

Exclusion Criteria:

- Renal failure,

- Secondary hyperparathyroidism,

- Primary hyperparathyroidism,

- thyroid lobectomy,

- Thyroid reoperation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prophylactic protocol with Ca and Vit D
3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet

Locations

Country Name City State
Greece "Korgialenio-Benakio", Hellenic Red Cross Athens General Hospital, Athens

Sponsors (1)

Lead Sponsor Collaborator
Hellenic Red Cross Hospital

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary blood calcium levels (mg/dl) on the 1st postoperative day blood calcium measured in a blood sample in mg/dl From the end of the operation until 24 hours after the operation
Primary blood calcium levels (mg/dl) on the 2nd postoperative day blood calcium measured in a blood sample in mg/dl From the end of the operation until 48 hours after the operation
Primary Length of hospital stay in days how many days the patient remained in the hospital From the day of the operation until a week after the operation
Secondary Overall cost of the treatment ( euros) how did this practice affected the cost of treatment of the patients From the day of the operation until a month from the operation
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05975866 - The Effects of an Anti-inflammatory Diet With or Without Curcumin Supplementation on Anthropometric Measurements, Concentrations of Thyroid Hormones, Anti-TPO, and Systemic Inflammation in Plasma and NFK-B in Peripheral Blood Mononuclear Cells in Patients With Hashimato N/A
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Completed NCT00569920 - Nausea and Pain Prophylaxis During Thyroid Surgery N/A
Recruiting NCT05917067 - Fluorescence Imaging of the Parathyroid Glands of Children
Completed NCT04704349 - Latest Imaging SPECT System Evaluation Phase 1 N/A
Recruiting NCT05430139 - Dried Blood Spot Testing for At Home Health
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT05678374 - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Not yet recruiting NCT04094493 - Vit D Role in Post Thyroidectomy Hypocalcemia Early Phase 1
Completed NCT03157466 - Respiratory Muscle Function After Thyroid Hormone Replacement Therapy in Nonthyroidal Illness Syndrome
Completed NCT04542278 - Preoperative Steroids in Autoimmune Thyroid Disease Phase 4
Completed NCT04425512 - Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy N/A
Recruiting NCT05510609 - Three-dimensional Ultrasonography Thyroid Volume Measurement. N/A
Recruiting NCT05412680 - Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) N/A
Completed NCT06227819 - BVA-200 vs BVA-100 Validation Study
Completed NCT00150033 - Health-Related Quality of Life for Thyroid Patients Phase 2
Active, not recruiting NCT04351945 - Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases